Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

Technology appraisal guidance
Reference number: TA836
Published: 26 October 2022

History

Final draft guidance

Final draft guidance
Final appraisal document (PDF 189 KB)

Published:

23 September 2022
Public committee slides (PDF 1.11 MB)

Published:

23 September 2022
Committee papers (PDF 3.76 MB)

Published:

23 September 2022

Invitation to participate

Final scope (PDF 240 KB)

Published:

14 January 2022
Final stakeholder list (PDF 236 KB)

Published:

14 January 2022
Equality impact assessment (Scoping) (PDF 128 KB)

Published:

14 January 2022
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 127 KB)

Published:

14 January 2022

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft scope post referral (PDF 262 KB)

Published:

13 December 2021
Draft matrix post referral (PDF 235 KB)

Published:

13 December 2021

Final draft guidance: TA619

Final appraisal document - TA619 (PDF 286 KB)

Published:

28 November 2019
Committee papers - TA619 (PDF 7.6 MB)

Published:

28 November 2019
Public committee slides - TA619 (PDF 3.22 MB)

Published:

28 November 2019
Final appraisal document - managed access agreement - TA619 (PDF 381 KB)

Published:

28 November 2019
Equality impact assessment - TA619 (PDF 123 KB)

Published:

15 January 2020
Register of interests - TA619 (PDF 131 KB)

Published:

17 February 2020

Invitation to participate

Final scope - TA619 (PDF 350 KB)

Published:

08 February 2019
Final stakeholder list - TA619 (PDF 234 KB)

Published:

11 September 2019
NICE's response to comments on the draft scope and provisional stakeholder list - TA619 (PDF 185 KB)

Published:

08 February 2019
Equality impact assessment (Scoping) - TA619 (PDF 176 KB)

Published:

08 February 2019